insights_auto
Why is GRAL up 33.68%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$107.97
arrow_upward
+33.68%(+27.20) 1D
$110.00
arrow_upward
+1.88% (+2.03)bedtimeAfter hours
Closed: Sep 21, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$93.74
High
$111.50
Low
$92.00
Mkt. cap
4.82B
Avg. vol.
864.08K
Volume
3.53M
52-wk high
$118.84
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$93.74
High
$111.50
Low
$92.00
Mkt. cap
4.82B
Avg. vol.
864.08K
Volume
3.53M
52-wk high
$118.84
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
Yahoo Finance
·
4 hours ago
GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes
Timothy Sykes
·
4 hours ago
GRAL Stock Breaks Out As Traders Eye Fresh Momentum
Stock Titan
·
4 hours ago
Up to $5.8M in insider stock may be sold at GRAIL, Inc. (GRAL)
News Corp
·
4 hours ago
Grail Stock Soars 34% Ahead of Multi-Cancer Blood Test Review From FDA
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com